This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Rozanolixizumab
DrugBank Accession Number
DB14919
Background

Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).

Type
Biotech
Groups
Investigational
Synonyms
  • Rozanolixizumab

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Rozanolixizumab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Rozanolixizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Rozanolixizumab.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rozanolixizumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Rozanolixizumab.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rozanolixizumab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Rozanolixizumab.
Allogeneic processed thymus tissueThe therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Rozanolixizumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
P7186074QC
CAS number
1584645-37-3

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentMyasthenia Gravis, Generalized1
3CompletedTreatmentMyasthenia Gravis, Generalized2
3Enrolling by InvitationTreatmentPrimary Immune Thrombocytopenia (ITP)1
3RecruitingTreatmentMyelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)1
3RecruitingTreatmentPrimary Immune Thrombocytopenia (ITP)2
2CompletedTreatmentChronic Inflammatory Demyelinating Polyradiculoneuropathy2
2CompletedTreatmentMyasthenia Gravis1
2RecruitingTreatmentLeucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis1
1CompletedBasic ScienceHealthy Study Participants1
1CompletedBasic ScienceHealthy Subjects (HS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:35 / Updated at February 21, 2021 18:55